CHRS Q1 2026 Earnings Transcript

Coherus Oncology reported Q1 Loqtorzi net sales of $11.8 million, up 61% year over year, despite a sequential dip from $12.4 million in Q4 due to seasonality and severe winter storms that disrupted treatment cycles. Management said new patient starts hit an all-time high, breadth/depth of ordering accounts rose 21%, and Loqtorzi demand is still expected to grow 10%-15% per quarter on average in 2026, with targets of $15 million quarterly sales in 2026 and $30 million-$35 million in 2027. The company also completed enrollment in the 72-patient CATALYST-202 study and ended the quarter with $167 million in cash and investments after a $54 million equity raise, funding operations through key readouts in 2026-2027.

Analysis

The setup is less about this quarter’s modestly choppy commercial print and more about a de-risking arc across three clocks: near-term Loqtorzi utilization, midyear clinical readouts, and 2027 funding runway. The important second-order signal is that management now has enough claims visibility to target the “leakage” buckets in NPC—chemo-only use and off-label PD-1 use—which means incremental sales should become less dependent on pure market growth and more on share capture. That makes the commercial curve more durable than the headline Q1 number suggests, especially if treatment duration keeps compounding from the growing first-line mix.

The real equity inflection is probably the midyear catalyst stack. CATALYST-202 is no longer an enrollment story; it becomes a biomarker/efficacy attribution story, and that matters because a credible IL-27/ctDNA signal could validate casdozo as more than a one-off HCC add-on. For tagmoketug, the market is likely underestimating how much program quality differentiation can matter in a crowded CCR8 field: if competing assets are stalling due to PK/safety or weak target engagement, CHRS can emerge as one of the few “survivors,” which would compress development risk and improve partnering optionality.

The main bear case is timing mismatch: the stock can still drift if the market insists on waiting for durable response data rather than initial ORR reads, and the HCC biomarker story may not translate quickly enough into valuation. A second risk is that the commercial guidance implicitly assumes weather/seasonality normalizes, but any repeat disruption would expose how much of the current growth is cycle recovery versus true acceleration. The key contrarian point: this is not a story about one launch; it is a platform monetization setup where even a mediocre first readout can keep the pipeline financed long enough for a better second act.

Key Decisions for Investors

• Long CHRS into the midyear catalyst window; consider a staged entry over the next 2-3 weeks, targeting upside from de-risking across Loqtorzi, CATALYST-202, and TAGMO. Risk/reward improves if shares remain range-bound ahead of data.
• Buy CHRS Aug/Sep call spreads rather than outright stock if implied volatility stays muted; the setup is binary enough that limited premium outlay is preferable to delta-only exposure.
• Pair trade: long CHRS vs short AMGN on CCR8 divergence over the next 3-6 months. If CHRS shows clean PK/safety and any response durability, the market should reward the platform while penalizing failed peers.
• If you already own CHRS, trim only on a strong pre-data rally; do not chase strength until after initial midyear readouts, because the first releases are likely to be noisy and low-N.
• Use a hedge with short-dated puts if you are long into the August guidance update, as weather-normalization risk and any revenue reset could create a sell-the-news move.